AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares traded up 11.9% during mid-day trading on Friday . The stock traded as high as $3.15 and last traded at $3.10. 3,615,965 shares changed hands during mid-day trading, an increase of 150% from the average session volume of 1,446,457 shares. The stock had previously closed at $2.77.
Several research analysts have issued reports on the company. Zacks Investment Research lowered AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th. Seaport Global Securities reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a report on Friday, October 6th. B. Riley assumed coverage on AVEO Pharmaceuticals in a report on Monday, November 13th. They issued a “buy” rating and a $5.00 price target on the stock. assumed coverage on AVEO Pharmaceuticals in a report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 price target on the stock. Finally, BidaskClub lowered AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $4.05.
The stock has a market cap of $366.80, a price-to-earnings ratio of -4.37 and a beta of 1.14. The company has a debt-to-equity ratio of -0.32, a current ratio of 2.33 and a quick ratio of 2.33.
ILLEGAL ACTIVITY NOTICE: “AVEO Pharmaceuticals (AVEO) Trading 11.9% Higher” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2018/01/14/aveo-pharmaceuticals-aveo-trading-11-9-higher.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
What are top analysts saying about AVEO Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AVEO Pharmaceuticals and related companies.